Hormonal
Preoperative GLP-1 RA therapy (4–8 weeks) reduces liver volume and visceral fat to improve surgical access, provided treatment is discontinued 1 week prior to surgery to mitigate aspiration risk.
If you are scheduled for bariatric surgery and take GLP-1 medications (like Ozempic or Wegovy), you must stop taking them at least one week before your operation. This is not optional; it is a safety requirement to prevent stomach contents from entering your lungs during anesthesia. The goal of this pre-surgery treatment is to shrink your liver and make the surgery technically easier and safer for the surgeon, not necessarily to prevent surgical complications like leaks.
A 4–8 week course of GLP-1 RAs during this neoadjuvant phase effectively reduces liver volume and visceral fat [15]. This optimization improves surgical access to the hiatus and decreases the risk of iatrogenic liver traction injuries... adherence to the 2024 American Society of Anesthesiologists consensus, which strongly recommends a 1-week hard stop protocol for weekly GLP-1 formulations prior to surgery [18], is a nonnegotiable requirement.
Why this rating
Based on a review article citing observational/multicenter studies (Indiana study) and consensus guidelines, not a primary RCT of the specific protocol.
Source
The onco-bariatric paradigm: a tri-phasic metabolic obesity framework for synergizing glucagon-like peptide-1 receptor agonists and metabolic bariatric surgery
Dong Jin Park et al. · Kosin Medical Journal · 2026
DOI 10.7180/kmj.26.154
More from this paper
- Metabolic bariatric surgery (MBS) is more cost-effective than continuous GLP-1 pharmacotherapy, saving an average of $11,689 per patient over 2 years, while providing a definitive metabolic reset.Good
- Adjuvant GLP-1 RA therapy combined with high-protein intake (≥1.2 g/kg/day) and resistance training is necessary to counteract metabolic adaptation and preserve lean body mass after bariatric surgery.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →